Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026 catalysts – MAVERIC Phase III enrollment progress, full ARCHER data, and CRD-38 clinical initiation – are key value drivers in…
On Thursday (September 11), Canadian Prime Minister Mark Carney revealed the first tranche of projects selected by the newly…
Gold’s record-setting price run continued this week, with yet another new all-time high in the books. Silver also fared…
Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the ‘Company’ or ‘Bold’) is pleased to announce the results of a prospecting and…
Highlights: The latest drill results build on Bo_RC_14/25 drill hole (previously released as 12.0 metres @ 4.27% WO₃ from…
Vancouver, British Columbia September 11, 2025 Rio Silver Inc. (‘Rio Silver’ or the ‘Company’) (TSX.V: RYO,OTC:RYOOD) (OTC: RYOOF) announces…
Brings Company’s Total Claims to 491 in Area Housing the Only Rare Earths Producing Mine in U.S. Move Expands…
Newmont (TSX:NGT,NYSE:NEM,ASX:NEM) is preparing to withdraw from the Toronto Stock Exchange later this month, the latest in a string…
Here’s a quick recap of the crypto landscape for Wednesday (September 10) as of 9:00 p.m. UTC. Get the…